Analyzing Portola Pharmaceuticals (PTLA) and Its Peers

Portola Pharmaceuticals (NASDAQ: PTLA) is one of 197 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Portola Pharmaceuticals to similar businesses based on the strength of its valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Volatility & Risk

Portola Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Portola Pharmaceuticals’ peers have a beta of 1.63, indicating that their average share price is 63% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Portola Pharmaceuticals and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Portola Pharmaceuticals 0 1 7 0 2.88
Portola Pharmaceuticals Competitors 471 2238 6133 118 2.66

Portola Pharmaceuticals presently has a consensus target price of $67.67, indicating a potential upside of 31.60%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.91%. Given Portola Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Portola Pharmaceuticals is more favorable than its peers.

Insider & Institutional Ownership

85.0% of Portola Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 4.9% of Portola Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Portola Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Portola Pharmaceuticals $31.93 million -$251.01 million -11.30
Portola Pharmaceuticals Competitors $207.78 million -$2.31 million 0.49

Portola Pharmaceuticals’ peers have higher revenue and earnings than Portola Pharmaceuticals. Portola Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Portola Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Portola Pharmaceuticals -807.93% -145.12% -78.93%
Portola Pharmaceuticals Competitors -3,971.40% -118.78% -44.07%


Portola Pharmaceuticals peers beat Portola Pharmaceuticals on 7 of the 12 factors compared.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply